Following a European reassessment of the fluoroquinolones, information regarding their long-lasting adverse effects has been strengthened, and their indications have been restricted. The fluoroquinolones form a relatively homogeneous group of broad-spectrum antibiotics, which are generally effective in systemic infections (1). In France, as of 3 April 2019, six fluoroquinolones were available for oral or parenteral administration: ciprofloxacin, lomefloxacin, moxi-floxacin, norfloxacin, ofloxacin and one of its iso-mers, levofloxacin. Before the arrival of the fluoroquinolones, the first generation quinolones, such as flumequin, were used in urinary tract infections (1).
展开▼
